TRAIL R2 Overview
Molecule Name
Tumor necrosis factor receptor superfamily member 10B
Synonyms
TNFRSF10B,TRAILR2,TRAIL-R2,CD262,DR5,KILLER,TRICK2,ZTNFR9,TRICKB
Drug Development Progress
Drugs in Clinical Trials10
Approved Drugs1
Highest Development StageApproved
Target Synonym
Tumor necrosis factor receptor superfamily member 10B，CD262，DR5，KILLER，TRAILR2，Death receptor 5，TRAIL-R2，UNQ160/PRO186，TNFRSF10B，TNF Receptor Superfamily Member 10b，TNF-Related Apoptosis-Inducing Ligand Receptor 2，TRICK2，ZTNFR9，P53-Regulated DNA Damage-Inducible Cell Death Receptor(Killer)，Tumor Necrosis Factor Receptor-Like Protein ZTNFR9，Death Domain Containing Receptor For TRAIL/Apo-2L，Apoptosis Inducing Protein TRICK2A/2B，Apoptosis Inducing Receptor TRAIL-R2，Cytotoxic TRAIL Receptor-2，Fas-Like Protein，TRAIL Receptor 2，CD262 Antigen，KILLER/DR5，TRICK2A，TRICK2B，TRICKB，Tumor Necrosis Factor Receptor Superfamily， Member 10b
Background
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) is also known as TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2), Death receptor 5 (DR5), CD262, KILLER, is a member of the TNF-receptor superfamily, and contains an intracellular death domain. TNFRSF10B / DR-5 is widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines. TRAILR2 / CD262 / DR5 is the receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD (a death domain containing adaptor protein) of TRAIL-R2 / TNFRSF10B recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. CD262 / DR5 Promotes the activation of NF-kappa-B. DR5 is essential for ER stress-induced apoptosis and is regulated by p53/TP53.
TRAIL R2 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Dulanermin (Shanghai GeBaiDe) | Phase 3 Clinical | Shanghai Gebaide Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
| Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) | Phase 3 Clinical | Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd | Neoplasms | Details | |
| TLY-012 | TLY-012 | Phase 1 Clinical | Theraly Fibrosis | Fibrosis; Liver Cirrhosis; Pancreatitis; Pancreatitis, Chronic; Scleroderma, Systemic | Details |
| BI-905711 | BI-905711 | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Cholangiocarcinoma; Gastrointestinal Neoplasms; Pancreatic Neoplasms | Details |
| Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma) | CTB-006 | Phase 1 Clinical | Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd | Solid tumours | Details |
| Ozekibart | JCT-205; INBRX-109 | Phase 1 Clinical | Inhibrx Inc | Adenocarcinoma | Details |
| TRAILR2/CDH3 bispecific antibody (Boehringer Ingelheim) | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Neoplasms | Details | |
| RC-248 | RC-248; RC248 | Phase 1 Clinical | Solid tumours | Details | |
| IBI-3004 | IBI-3004; IBI3004 | Phase 1 Clinical | Colorectal Neoplasms; Solid tumours | Details | |
| Oba-01 | Oba-01; Oba01 | Phase 1 Clinical | Yantai Heyuanaidisi Biomedical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Aponermin | Approved | Beijing Shadong Biotech Co Ltd | 沙艾特, Shaite | Mainland China | Multiple Myeloma | Wuhan Hiteck Biological Pharma Co Ltd | 2023-11-02 | Multiple Myeloma | Details |